Comments
Glenmark Pharmaceuticals said it has received final approval from the US health regulator for the generic version of Temovate cream used to treat inflammation and itching caused by a number of skin conditions.
“Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate cream USP, 0.05%, the generic version of Temovate Cream, 0.05%, of Fougera Pharmaceuticals, the company said in a BSE filing.
For the 12 months to March 2018, Temovate cream achieved annual sales of approximately $118 million, Glenmark said, citing IQVIA sales data. The company’s current portfolio consists of 134 products authorised for distribution in the US marketplace and 61 abbreviated new drug applications (ANDA) pending approval with the USFDA. Glenmark shares were trading 1.75 per cent lower at Rs 507 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.